ArticleBioactive materials2021
Supramolecular co-assembly of self-adjuvanting nanofibrious peptide hydrogel enhances cancer vaccination by activating MyD88-dependent NF-κB signaling pathway without inflammation.
Article in Bioactive materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- In situ reprogramming of CAR-alveolar macrophages via liposomal nanomedicine for lung cancer immunotherapy.Nature communications · 2026Article
- Review
- Engineered self-assembling hydrogel systems for advanced guided bone regeneration: structural optimization and biofunctional modulation.Journal of nanobiotechnology · 2025Review
- Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors.Materials today. Bio · 2025Article
- Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen.Advanced functional materials · 2025Article
- Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8Journal for immunotherapy of cancer · 2024Article
- Review
- Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024Review
- Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery.Advanced healthcare materials · 2023Review
- Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy.Nano-micro letters · 2023Review
- Peptide-drug co-assembling: A potent armament against cancer.Theranostics · 2023Review
- Research progress of nanovaccine in anti-tumor immunotherapy.Frontiers in oncology · 2023Review
- Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy.Bioactive materials · 2022Review
- Peptide-Based Hydrogels: New Materials for Biosensing and Biomedical Applications.Materials (Basel, Switzerland) · 2022Review
- Self-adjuvanting cancer nanovaccines.Journal of nanobiotechnology · 2022Review
- Self-Stabilized Supramolecular Assemblies Constructed from PEGylated Dendritic Peptide Conjugate for Augmenting Tumor Retention and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide vaccine targeting tumor-specific antigens is a promising cancer treatment regimen. However, peptide vaccines are commonly low-immunogenic, leading to suboptimal antitumor T-cell responses. Current peptide vaccination approaches are challenged by the variability of peptide physicochemical characters and vaccine formulations, flexibility, and the broad feasibility. Here, the supramolecular co-assembly of antigen epitope-conjugated peptides (ECPs) targeting CD8 or CD4 T-cell receptors was used to engineer a nanofibrious hydrogel vaccine platform. This approach provided precise and tunable loading of peptide antigens in nanofibers, which notably increased the antigen uptake, cross-presentation, and activation of dendritic cells (DCs). Immunization in mice indicated that the co-assembled peptide hydrogel did not induce local inflammation responses and elicited significantly promoted T-cell immunity by activating the MyD88-dependent NF-κB signaling pathway in DCs. Vaccination of mice using co-assembled peptide vaccine stimulated both enhanced CD8 and CD4 T cells against EG.7-OVA tumors without additional immunoadjuvants or delivery systems, and resulted in a more remarkable cancer immunotherapy efficacy, compared with free peptide vaccine or aluminum-adjuvanted peptide formulation. Altogether, peptide co-assembly demonstrated by three independent pairs of ECPs is a facile, customizable, and chemically defined approach for co-delivering peptide antigens in self-adjuvanting hydrogel vaccines that could induce stronger anticancer T-cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.